Ovarian sarcoma

Summary

Ovarian sarcoma (MONDO:0002225) is a cancer and 18 clinical trials. Top therapeutic interventions include sorafenib, vismodegib, and tanespimycin. A subtype of ovarian cancer — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Classification: Cancer
• Clinical trials: 18

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	ovarian sarcoma
Mondo ID	MONDO:0002225
DOID	DOID:2146
NCIT	C8267
SNOMED CT	423627007
UMLS	C0280746
MedGen	128881
GARD	0023091
Anatomy (UBERON)	UBERON:0000992
Is cancer (heuristic)	yes

Also known as: ovarian sarcoma · ovary sarcoma · sarcoma of ovary · sarcoma of the ovary

Disease family

This is a subtype of ovarian cancer. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › cancer › reproductive system cancer › female reproductive organ cancer › ovarian cancer › ovarian sarcoma

Related subtypes (10): ovarian malignant mesothelioma, malignant ovarian cyst, ovarian lymphoma, ovarian Wilms tumor, ovarian neuroendocrine neoplasm, ovarian adenosarcoma, ovarian endometrioid adenocarcinofibroma, familial ovarian cancer, malignant epithelial tumor of ovary, malignant non-epithelial tumor of ovary

Subtypes (4): ovary rhabdomyosarcoma, ovarian angiosarcoma, ovary leiomyosarcoma, liposarcoma of the ovary

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 18.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE2	6
PHASE1	5
Not specified	5
PHASE1/PHASE2	2

Top trials by phase / activity

NCT	Phase	Status	Title
NCT07067255	PHASE1/PHASE2	RECRUITING	Sequential CD146 and GPC3 CAR-T Cell Therapy in Advanced Ovarian Cancer
NCT00245102	PHASE2	COMPLETED	Sorafenib in Treating Patients With Metastatic, Locally Advanced, or Recurrent Sarcoma
NCT00390234	PHASE2	COMPLETED	Ziv-aflibercept in Treating Patients With Locally Advanced, Unresectable, or Metastatic Gynecologic Soft Tissue Sarcoma
NCT01079832	PHASE2	COMPLETED	Stereotactic Radiosurgery Using CyberKnife in Treating Women With Advanced or Recurrent Gynecological Malignancies
NCT01154452	PHASE1/PHASE2	COMPLETED	Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma
NCT01283035	PHASE2	COMPLETED	A Phase II Study of Akt Inhibitor MK2206 in the Treatment of Recurrent Platinum-Resistant Ovarian, Fallopian Tube, or Peritoneal Cancer
NCT01553539	PHASE2	COMPLETED	Therapeutic Angiotensin-(1-7) in Treating Patients With Metastatic Sarcoma That Cannot Be Removed By Surgery
NCT01764802	PHASE2	COMPLETED	Psychosexual Intervention in Patients With Stage I-III Gynecologic or Breast Cancer
NCT00004241	PHASE1	COMPLETED	17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Advanced Epithelial Cancer, Malignant Lymphoma, or Sarcoma
NCT00020267	PHASE1	COMPLETED	Vaccine Therapy in Treating Patients With Metastatic Cancer
NCT00031681	PHASE1	COMPLETED	7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007)
NCT00408655	PHASE1	COMPLETED	Temsirolimus, Carboplatin, and Paclitaxel in Treating Patients With Advanced Solid Tumors
NCT01652794	PHASE1	COMPLETED	Carboplatin, Gemcitabine Hydrochloride, and Stereotactic Body Radiation Therapy in Gynecological Cancer
NCT03382158	Not specified	RECRUITING	International PPB/DICER1 Registry
NCT00087191	Not specified	TERMINATED	EF5 and Motexafin Lutetium in Detecting Tumor Cells in Patients With Abdominal or Non-Small Cell Lung Cancer
NCT01080521	Not specified	COMPLETED	Changes in Brain Function in Patients With Stage I, Stage II, Stage III, or Stage IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Who Are Receiving Chemotherapy
NCT01126346	Not specified	COMPLETED	Quality of Life and Survivorship Care in Patients Undergoing Hyperthermic Intraperitoneal Chemotherapy (HIPEC)
NCT01764789	Not specified	COMPLETED	Stress Reduction in Improving Quality of Life in Patients With Recurrent Gynecologic or Breast Cancer

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
SORAFENIB	4	1
VISMODEGIB	4	1
TANESPIMYCIN	3	1
TALFIRASTIDE	2	1
UCN-01	2	1
CHEMBL4786163	0	1
CHEMBL1236539	0	1
MOTEXAFIN LUTETIUM	-1	1